Rapport Therapeutics (RAPP) · RAP-219 / bipolar mania Phase 2 · Topline results
Narrower window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: in the fourth quarter of 2026
topline results are now expected in the fourth quarter of 2026
SEC , Exhibit 99.1 · filed · SEC filing
After
Stated timing: in October 2026
topline results expected in October 2026
SEC 8-K, Exhibit 99.1 · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/RAPP-rap-219-bipolar-mania-phase-2-topline-results-2026-08-05, data as of Oct 12, 2026
https://www.orionbiotechai.com/changes/RAPP-rap-219-bipolar-mania-phase-2-topline-results-2026-08-05
Rapport Therapeutics (RAPP) pipeline and stated timing · Calendar · Companies A–Z
A Form 8-K is a report a company files with the SEC to announce a significant event between its regular reports.